Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Immuneering Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- ATEBIMETINIB SHOWED BROAD ANTITUMOR ACTIVITY ACROSS KRAS-, NRAS-, AND BRAF-MUTANT MODELS, INCLUDING COLORECTAL, LUNG, AND MELANOMA, BY RESISTING THE RAF-MEDIATED BYPASS SIGNALING THAT HAS CONSTRAINED OTHER MEK INHIBITORS -

PUBLICATION IN CANCER RESEARCH DETAILS ATEBIMETINIB'S BROAD, DURABLE PRECLINICAL ACTIVITY AND FAVORABLE TOLERABILITY ACROSS RAS- AND RAF-MUTANT TUMORS VIA DEEP CYCLIC INHIBITION

NEW YORK, JULY 17, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, PREVIOUSLY ANNOUNCED ON JUNE 15, 2026, THAT ANDREW GENGOS WAS NAMED CHIEF FINANCIAL OFFICER OF THE COMPANY, EFFECTIVE AS OF JULY 16, 2026 (THE START DATE). IN CONNECTION WITH THE COMMENCEMENT OF MR.

IMMUNEERING CORPORATION ANNOUNCES GRANTS OF INDUCEMENT AWARDS

- FORMER CFO OF TERNS PHARMACEUTICALS TO JOIN IMMUNEERING - - SEASONED PUBLIC COMPANY CFO STRENGTHENS TEAM WITH OVER 25 YEARS OF LEADERSHIP IN BIOTECH  NEW YORK, JUNE 15, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THE APPOINTMENT OF ANDREW GENGOS AS CHIEF FINANCIAL OFFICER, EFFECTIVE JULY 16, 2026. MR. GENGOS MOST RECENTLY SERVED AS CHIEF FINANCIAL OFFICER AND HEAD OF CORPORATE DEVELOPMENT AT TERNS PHARMACEUTICALS, WHICH MERCK & CO., INC. ACQUIRED FOR $6.7 BILLION.

IMMUNEERING APPOINTS ANDREW GENGOS AS CHIEF FINANCIAL OFFICER

GLOBAL PIVOTAL PHASE 3 TRIAL WILL EVALUATE EFFICACY AND SAFETY OF ATEBIMETINIB + MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) COMPARED TO STANDARD GNP ALONE TOPLINE DATA READOUT, INCLUDING PRIMARY ENDPOINT OF OVERALL SURVIVAL, ANTICIPATED IN MID-2028 NEW YORK, JUNE 11, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN MAPKEEPER 301, A GLOBAL, RANDOMIZED, OPEN-LABEL PIVOTAL PHASE 3 CLINICAL TRIAL EVALUATING ATEBIMETINIB PLUS MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) IN FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS. ATEBIMETINIB IS A NOVEL MEK INHIBITOR WITH A PULSATILE MECHANISM DESIGNED TO TARGET RAS, RAF, AND OTHER MAPK PATHWAY-DRIVEN CANCERS WITH GREATER DURABILITY AND TOLERABILITY THAN TRADITIONAL CHRONIC INHIBITORS.

IMMUNEERING ANNOUNCES FIRST PATIENT DOSED IN PIVOTAL PHASE 3 MAPKEEPER 301 TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER

IMMUNEERING PRESENTS COMPELLING 17.3-MONTH MEDIAN OVERALL SURVIVAL AND FAVORABLE TOLERABILITY WITH ATEBIMETINIB + CHEMOTHERAPY IN FIRST-LINE PANCREATIC CAN

IMMUNEERING PRESENTS COMPELLING 17.3-MONTH MEDIAN OVERALL SURVIVAL AND FAVORABLE TOLERABILITY WITH ATEBIMETINIB + CHEMOTHERAPY IN FIRST-LINE PANCREATIC CANCER PATIENTS AT ASCO

IMMUNEERING REPORTS 17.3 MONTHS MEDIAN OVERALL SURVIVAL IN FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB PLUS CHEMOTHERAPY

- NEW SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL EVALUATING ATEBIMETINIB + MGNP IN FIRST-LINE METASTATIC PANCREATIC CANCER TO BE PRESENTED IN AN ORAL SESSION AT 2026 ASCO ANNUAL MEETING - - PIVOTAL PHASE 3 MAPKEEPER 301 TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE METASTATIC PANCREATIC CANCER NOW RECRUITING (NCT07562152), WITH FIRST PATIENT DOSING ON TRACK FOR MID-2026 - - 27 MONTHS PROGRESSION-FREE SURVIVAL TO DATE IN A THIRD-LINE PANCREATIC CANCER PATIENT RECEIVING ATEBIMETINIB MONOTHERAPY, WITH AN ONGOING 85% REDUCTION IN TUMOR BURDEN  - ENDED Q1 2026 WITH $198.6 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WITH ANTICIPATED RUNWAY INTO 2029 - NEW YORK, MAY 15, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2026, AND PROVIDED BUSINESS UPDATES. "WE ARE EXCITED THAT NEW SURVIVAL DATA FROM 55 FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP IN OUR PHASE 2A CLINICAL TRIAL WILL BE REPORTED IN AN ORAL PRESENTATION AT THE ASCO ANNUAL MEETING ON JUNE 1ST, SAID BEN ZESKIND, CHIEF EXECUTIVE OFFICER OF IMMUNEERING.

IMMUNEERING REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

- NEW DATA FROM PHASE 2A CLINICAL TRIAL EVALUATING ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER WILL BE PRESENTED IN AN ORAL SESSION BY DR. PETER VU, UC SAN DIEGO HEALTH -

IMMUNEERING TO PRESENT NEW SURVIVAL DATA FROM FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP IN AN ORAL PRESENTATION AT THE 2026 ASCO ANNUAL MEETING

ANALYSIS OF CIRCULATING TUMOR DNA FROM ATEBIMETINIB-TREATED PATIENTS SHOWS ACQUIRED MAPK PATHWAY ALTERATIONS ARE RARE, SUPPORTING OBSERVED DURABLE FIRST-LINE ACTIVITY ATEBIMETINIB-TREATED TUMORS RARELY ACQUIRE THE GENETIC ALTERATIONS MOST COMMONLY ASSOCIATED WITH RESISTANCE TO RAS INHIBITORS, PROVIDING MOLECULAR RATIONALE TO TREAT WITH ATEBIMETINIB EARLY NEW YORK, APRIL 20, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THE PRESENTATION OF NEW GENETIC DATA AT THE 2026 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING TAKING PLACE APRIL 17-22, 2026 IN SAN DIEGO, CA. ATEBIMETINIB IS DESIGNED TO PROMOTE SURVIVAL BY THREE MECHANISMS: SHRINKING TUMORS DURABLY, PRESERVING BODY MASS BY COUNTERACTING MUSCLE WASTING, AND MAINTAINING PERFORMANCE STATUS BY MAXIMIZING TOLERABILITY, SAID BEN ZESKIND, PH.D.

IMMUNEERING PRESENTS GENETIC DATA AT AACR ANNUAL MEETING DEMONSTRATING MECHANISM TO IMPROVE DURABILITY AND SURVIVAL, SUPPORTING USE OF ATEBIMETINIB IN FIRST-LINE PANCREATIC CANCER AND BEYOND

NEW YORK, APRIL 06, 2026 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLINICAL ONCOLOGY COMPANY FOCUSED ON KEEPING CANCER PATIENTS ALIVE AND HELPING THEM THRIVE, TODAY ANNOUNCED THAT BEN ZESKIND, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON MONDAY, APRIL 13, 2026 AT 3:45 P.M. ET.THE FIRESIDE CHAT WILL BE WEBCAST LIVE AND ARCHIVED IN THE INVESTOR RELATIONS SECTION OF IMMUNEERING'S WEBSITE AT EVENTS & PRESENTATIONS | IMMUNEERING CORPORATION.

Immuneering Corporation

IMRX

Price

Financial Reports

No items found.

Press Releases

Immuneering Corporation

IMRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMRX